LOXO ONCOLOGY, INC.

FDA Grants Full Approval to Selpercatinib for RET-Mutant Medullary Thyroid Cancer

8 months ago

• The FDA granted traditional approval to selpercatinib (Retevmo) for advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation in patients 2 years and older. • The approval was based on the LIBRETTO-531 trial, which demonstrated superior progression-free survival compared to cabozantinib or vandetanib. • Patients on selpercatinib reported less time with severe side effect bother than those on cabozantinib or vandetanib, improving overall tolerability. • Selpercatinib is now a preferred first-line treatment option for advanced RET-mutant medullary thyroid cancer, offering a targeted approach.